Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vancomycin after catheter replacement for suspected CLABSI
NCT04856878Phase 4Unknown
- Sponsor
- University of Zurich
- Start
- Jun 2021
- Primary completion
- Jun 2024
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
01
Overview
Phase 4, randomised, open-label trial of vancomycin in central line-associated bloodstream infection (CLABSI) (2 arms), sponsored by University of Zurich. Primary endpoint: Resolution of infection at 96 hours. Status: unknown.
02
Drugs
vancomycin
03
Conditions
central line-associated bloodstream infection (CLABSI)
Beyond the preview
Go deeper on NCT04856878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856878.